<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04217668</url>
  </required_header>
  <id_info>
    <org_study_id>HR002 Provocation</org_study_id>
    <nct_id>NCT04217668</nct_id>
  </id_info>
  <brief_title>Headache Provocation of People Who Are Unable to Have Headache</brief_title>
  <official_title>Pain Perception, Headache Provocation and Multiomics of People Who Are Unable to Have Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Headaches are extremely common illnesses with a combined lifetime prevalence of 90-99% in
      Europe. Despite this high prevalence, there are persons who have never, in their whole life,
      encountered a headache.

      The aim of the study is to identify factors that protect against headache by studying
      headache after provocation in people who never have had a headache (headache resistant)
      versus non-resistant controls.

      The investigators will use isosorbide mononitrate as a pharmacological trigger of headache.
      The provocation is performed by investigators who are blinded to the grouping of the
      participants.

      The investigators hope to contribute with novelty to the current understanding of headache
      pathophysiology and development of more efficient treatment of headache.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Blinded case-control study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The investigators are blinded to the case-control grouping of the participants.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve of headache intensity</measure>
    <time_frame>5 hours</time_frame>
    <description>Area under the curve of headache intensity from 0 - 5 hours post tablet administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of headache intensity</measure>
    <time_frame>12 hours</time_frame>
    <description>Area under the curve of headache intensity from 0 - 12 hours post tablet administration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Headache</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Isosorbide mononitrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cases and controls both receive one tablet ImdurÂ® 60 mg (isosorbide mononitrate) on the study day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isosorbide Mononitrate 60 MG</intervention_name>
    <description>1 tablet Isosorbide Mononitrate 60 mg administrated orally.</description>
    <arm_group_label>Isosorbide mononitrate</arm_group_label>
    <other_name>Imdur</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Headache resistant and non-resistant male participants from the Danish Blood Donor
             Study.

          -  Weight: 45 kg to 95 kg

        Exclusion Criteria:

          -  Daily consumption of any medication.

          -  Consumption of any medication less than 12 hours prior to the study day.

          -  Headache on the study day or 48 hours prior to the study day.

          -  Amnestic or clinical signs of hypertension (systolic blood pressure &gt;150 mmHg and/or
             diastolic blood pressure &gt;100 mmHg) or hypotension (systolic blood pressure &lt;90 mmHg
             and/or diastolic blood pressure &lt;50 mmHg).

          -  Any severe cardiovascular disease, including cerebrovascular illness.

          -  Amnestic or clinical signs of current mental illness.

          -  Amnestic or clinical signs of current substance or drug abuse.

          -  Amnestic or clinical signs of any illness the responsible doctor considers relevant
             for participation in the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jes Olesen, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Danish Headache Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isa A Olofsson, MD</last_name>
    <phone>+45 38 63 20 62</phone>
    <email>isa.amalie.olofsson@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Danish Headache Center</name>
      <address>
        <city>Glostrup</city>
        <state>Region H</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isa A Olofsson, MD</last_name>
      <phone>+45 38 63 20 62</phone>
      <email>isa.amalie.olofsson@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Isa A Olofsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 2, 2020</study_first_submitted>
  <study_first_submitted_qc>January 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2020</study_first_posted>
  <last_update_submitted>January 2, 2020</last_update_submitted>
  <last_update_submitted_qc>January 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Isa Amalie Olofsson</investigator_full_name>
    <investigator_title>Medical Doctor, PhD student</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isosorbide</mesh_term>
    <mesh_term>Isosorbide Dinitrate</mesh_term>
    <mesh_term>Isosorbide-5-mononitrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

